https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-02-24 / Oncol Lett 2016 Apr;11(4):2605-2610
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-02-24 / Oncol Lett 2016 Apr;11(4):2605-26102016-02-24 00:00:002019-02-15 08:45:42Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-11-15 / Am J Cancer Res 2015;5(12):3612-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-11-15 / Am J Cancer Res 2015;5(12):3612-232015-11-15 00:00:002015-11-15 00:00:00Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-16 / Pharmacol. Ther. 2015 Sep;153:1-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-16 / Pharmacol. Ther. 2015 Sep;153:1-92015-05-16 00:00:002019-02-15 08:35:17Vaccine immunotherapy in lung cancer: Clinical experience and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-04 / Tumour Biol. 2015 Mar;36(3):1411-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-04 / Tumour Biol. 2015 Mar;36(3):1411-222015-03-04 00:00:002019-02-15 08:45:39Immunotherapy for lung cancer: for whom the bell tolls?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-16 / Int. Immunopharmacol. 2015 Apr;25(2):450-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-16 / Int. Immunopharmacol. 2015 Apr;25(2):450-62015-02-16 00:00:002019-02-15 08:45:38Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-15 / Mol Med Rep 2015 Jan;11(1):317-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-15 / Mol Med Rep 2015 Jan;11(1):317-262014-10-15 00:00:002014-10-15 00:00:00Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-15 / Mol Med Rep 2015 Jan;11(1):327-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-15 / Mol Med Rep 2015 Jan;11(1):327-322014-10-15 00:00:002019-02-15 09:18:18Inhibition of cell proliferation by mild hyperthermia at 43˚C with Paris Saponin I in the lung adenocarcinoma cell line PC-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-28 / Cancer Immunol. Immunother. 2015 Jan;64(1):51-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-28 / Cancer Immunol. Immunother. 2015 Jan;64(1):51-92014-09-28 00:00:002019-02-15 08:45:30Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-25 / Oncol Lett 2014 Dec;8(6):2569-2576
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-25 / Oncol Lett 2014 Dec;8(6):2569-25762014-09-25 00:00:002014-09-25 00:00:00Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-30 / BMC Cancer 2014 Jul;14:551
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-30 / BMC Cancer 2014 Jul;14:5512014-07-30 00:00:002014-07-30 00:00:00Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells
